United Capital Financial Advisers LLC reduced its stake in Boston Scientific Co. (NYSE:BSX – Get Rating) by 33.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,010 shares of the medical equipment provider’s stock after selling 3,510 shares during the period. United Capital Financial Advisers LLC’s holdings in Boston Scientific were worth $272,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in BSX. Newport Trust Co lifted its position in shares of Boston Scientific by 5,082.5% during the second quarter. Newport Trust Co now owns 7,401,817 shares of the medical equipment provider’s stock worth $275,866,000 after purchasing an additional 7,258,993 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of Boston Scientific by 24.5% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 20,806,144 shares of the medical equipment provider’s stock valued at $775,455,000 after acquiring an additional 4,088,589 shares during the period. Lazard Asset Management LLC increased its stake in shares of Boston Scientific by 23.6% during the second quarter. Lazard Asset Management LLC now owns 12,653,052 shares of the medical equipment provider’s stock valued at $471,578,000 after acquiring an additional 2,416,974 shares during the period. Arrowstreet Capital Limited Partnership grew its position in Boston Scientific by 65.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 5,430,814 shares of the medical equipment provider’s stock worth $240,531,000 after buying an additional 2,157,849 shares during the last quarter. Finally, Impax Asset Management Group plc grew its position in Boston Scientific by 47.5% in the third quarter. Impax Asset Management Group plc now owns 6,621,133 shares of the medical equipment provider’s stock worth $255,836,000 after buying an additional 2,132,468 shares during the last quarter. 90.23% of the stock is currently owned by institutional investors and hedge funds.
Boston Scientific Price Performance
NYSE:BSX opened at $47.02 on Wednesday. The firm has a market cap of $67.46 billion, a PE ratio of 104.49, a price-to-earnings-growth ratio of 2.25 and a beta of 0.79. Boston Scientific Co. has a 12 month low of $34.98 and a 12 month high of $48.87. The company has a quick ratio of 1.02, a current ratio of 1.51 and a debt-to-equity ratio of 0.51. The company’s 50-day moving average price is $46.63 and its two-hundred day moving average price is $43.89.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on BSX shares. Truist Financial lifted their price target on shares of Boston Scientific from $50.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, December 20th. Needham & Company LLC raised their price objective on shares of Boston Scientific from $48.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, February 2nd. StockNews.com raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Thursday, March 2nd. JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $48.00 to $55.00 and gave the stock an “overweight” rating in a research note on Thursday, February 2nd. Finally, TheStreet lowered shares of Boston Scientific from a “b-” rating to a “c” rating in a research note on Monday, November 28th. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $51.50.
Insider Buying and Selling at Boston Scientific
In other Boston Scientific news, CFO Daniel J. Brennan sold 75,610 shares of the business’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $46.64, for a total value of $3,526,450.40. Following the transaction, the chief financial officer now directly owns 255,958 shares in the company, valued at $11,937,881.12. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Boston Scientific news, CFO Daniel J. Brennan sold 75,610 shares of the company’s stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $46.64, for a total value of $3,526,450.40. Following the completion of the sale, the chief financial officer now owns 255,958 shares of the company’s stock, valued at $11,937,881.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 27,000 shares of the company’s stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $48.74, for a total transaction of $1,315,980.00. Following the completion of the sale, the executive vice president now directly owns 23,392 shares of the company’s stock, valued at approximately $1,140,126.08. The disclosure for this sale can be found here. Insiders have sold a total of 174,794 shares of company stock worth $8,193,941 over the last ninety days. Corporate insiders own 0.66% of the company’s stock.
Boston Scientific Company Profile
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.
Read More
- Get a free copy of the StockNews.com research report on Boston Scientific (BSX)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX – Get Rating).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
